JOHN FREDERICK DE GROOT to Vascular Endothelial Growth Factor A
This is a "connection" page, showing publications JOHN FREDERICK DE GROOT has written about Vascular Endothelial Growth Factor A.
Connection Strength
1.510
-
VEGF Manipulation in Glioblastoma. Oncology (Williston Park). 2015 Oct; 29(10):720-7.
Score: 0.324
-
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res. 2013 Aug 15; 19(16):4392-403.
Score: 0.277
-
Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81.
Score: 0.240
-
Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009 Jul 15; 15(14):4589-99.
Score: 0.210
-
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756.
Score: 0.091
-
Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188.
Score: 0.089
-
Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2014 Jan 01; 20(1):187-98.
Score: 0.071
-
Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 2012 Nov; 14(11):1379-92.
Score: 0.066
-
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95.
Score: 0.060
-
Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J. 2008 Sep-Oct; 14(5):279-85.
Score: 0.050
-
Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma. J Neurooncol. 2016 12; 130(3):495-503.
Score: 0.022
-
Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther. 2005 Nov; 4(11):1681-8.
Score: 0.010